The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC


The first attempt to quantify therapy-related myelodysplastic syndrome or acute myeloid leukemia in the era of widespread platinum-based chemotherapy has found that tMDS/AML risks were statistically significantly elevated after chemotherapy for 22 of 23 solid cancers, according to a new study in JAMA Oncology.

Latest JournalAll Journals >>

The Journal of Targeted Therapies in Cancer February 2019
The Journal of Targeted Therapies in Cancer
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.